Purification, biochemical properties and antithrombotic effect of a novel Streptomyces enzyme on carrageenan-induced mice tail thrombosis model

Simkhada, Jaya Ram; Cho, Seung‐Sik; Mander, Poonam; Choi, Yun Hee; Yoo, Jin Cheol

doi:10.1016/j.thromres.2011.09.014

Cited by 44 publications

(33 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This model has been extensively used to test the effect of several anti-thrombus and thrombolytic agents clinically (Yuan et al 2012;Yan et al 2009;Kamiya et al 2010;Simkhada et al 2012). Carrageenan is a linear sulphur containing polysaccharide, extracted from edible red seaweeds.…”

Section: Carrageenan-induced Thrombosis Modelmentioning

confidence: 99%

Methods available to assess therapeutic potential of fibrinolytic enzymes of microbial origin: a review

2018

View full text Add to dashboard Cite

Fibrinolytic enzymes are agents administered for the treatment of myocardial infarctions, strokes, cardiac and respiratory failure. Although several microorganisms are known to produce these fibrinolytic enzymes, only a few of such enzymes, along with the age-old oral anticoagulants, have been employed in the clinical and therapeutic applications in humans. The use of these agents is associated with drawbacks such as allergic reactions and bleeding complications; therefore, it necessitates frequent monitoring of drug levels in the blood. Due to this, there is an impetus on the current effort to identify newer potential candidates from the novel microbial sources which show longer half-life, higher fibrin specificity, higher therapeutic index and lesser allergic reactions. Various methods are available for the preliminary evaluation of a potential drug candidate for the therapeutic use. Choosing the right combination of in vitro and in vivo methods would give crucial insight on the therapeutic potential of the chosen test compound. This article discusses various assay techniques, in vitro trails and in vivo models available, to help researchers in choosing right biological methods and its combinations to evaluate efficacy of potential drug candidate.

show abstract

Section: Carrageenan-induced Thrombosis Modelmentioning

confidence: 99%

Methods available to assess therapeutic potential of fibrinolytic enzymes of microbial origin: a review

2018

View full text Add to dashboard Cite

show abstract

“…Most of these publications address the effects of anti-inflammatory treatments to alleviate carrageenan-induced inflammation, including effects of lactobacilli [16], but without specific attention to the mechanistic pathways by which carrageenan causes inflammation. Other reports consider a variety of topics, including the chemical characteristics of carrageenan as a gel in food products [17], the use of carrageenan hydrogels as therapeutic delivery vehicles [18], carrageenan as a therapy, including for the common cold [19], and thrombotic effects of carrageenan [20]. …”

Section: Introductionmentioning

confidence: 99%

Carrageenan-Induced Colonic Inflammation Is Reduced in Bcl10 Null Mice and Increased in IL-10-Deficient Mice

Bhattacharyya

Xue

Devkota

et al. 2013

Mediators of Inflammation

View full text Add to dashboard Cite

The common food additive carrageenan is a known activator of inflammation in mammalian tissues and stimulates both the canonical and noncanonical pathways of NF-κB activation. Exposure to low concentrations of carrageenan (10 μg/mL in the water supply) has produced glucose intolerance, insulin resistance, and impaired insulin signaling in C57BL/6 mice. B-cell leukemia/lymphoma 10 (Bcl10) is a mediator of inflammatory signals from Toll-like receptor (TLR) 4 in myeloid and epithelial cells. Since the TLR4 signaling pathway is activated in diabetes and by carrageenan, we addressed systemic and intestinal inflammatory responses following carrageenan exposure in Bcl10 wild type, heterozygous, and null mice. Fecal calprotectin and circulating keratinocyte chemokine (KC), nuclear RelA and RelB, phospho(Thr559)-NF-κB-inducing kinase (NIK), and phospho(Ser36)-IκBα in the colonic epithelial cells were significantly less (P < 0.001) in the carrageenan-treated Bcl10 null mice than in controls. IL-10-deficient mice exposed to carrageenan in a germ-free environment showed an increase in activation of the canonical pathway of NF-κB (RelA) activation, but without increase in RelB or phospho-Bcl10, and exogenous IL-10 inhibited only the canonical pathway of NF-κB activation in cultured colonic cells. These findings demonstrate a Bcl10 requirement for maximum development of carrageenan-induced inflammation and lack of complete suppression by IL-10 of carrageenan-induced inflammation.

show abstract

“…Table 4 shows the results of whole blood clotting time in vitro. We found that the accurately [38,39]. Table 4 shows that nattokinase-loaded SDEDDS formulations could significantly improve mouse tail thrombosis by reducing the mouse tail thrombosis average relative length (P<0.05).…”

Section: In Vitro Drug Release Studymentioning

confidence: 87%

Preparation and evaluation of nattokinase-loaded self-double-emulsifying drug delivery system

Wang

Jiang

Wang

et al. 2015

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Self-double-emulsifying drug delivery system was prepared by mixing water/oil emulsions with hydrophilic emulsifiers proportionally, which could self-emulsify into water/oil/water multiple emulsions followed by dilution with aqueous media under gastrointestinal motility or mild agitation at the ambient temperature. Nattokinase was encapsulated, then released in vitro and pharmacodynamics study in vivo. Abstract:In the present study, we prepared nattokinase-loaded self-double-emulsifying drug delivery system (SDEDDS) and investigated its preliminary pharmacodynamics.The type and concentration of oil phase, inner aqueous phase and emulsifier were screened to prepare optimum nattokinase-loaded SDEDDS. Next, the optimum formulations were characterized based on microstructure, volume-weighted mean droplet size, self-emulsifying rate, yield, storage stability, in vitro release and in vivo pharmacodynamics studies. The water/oil/water multiple emulsions exhibited typical multiple structure, with relatively small volume-weighted mean droplet size 6.0 ± 0.7 µm and high self-emulsifying ability (self-emulsifying time <2 min). Encapsulation of nattokinase was up to 86.8 ± 8.2%. The cumulative release of nattokinase within 8 h was about 30%, exhibiting a sustained release effect. The pharmacodynamics study indicated that nattokinase-loaded SDEDDS could significantly prolong the whole blood clotting time in mouse and effectively improve the carrageenan-induced tail thrombosis compared with nattokinase solution. Moreover, we showed that SDEDDS could successfully self-emulsify into water /oil/water multiple emulsions upon dilution in dispersion medium with gentle stirring and effectively protect nattokinase activity in gastric environment. Our findings suggested that SDEDDS could be a promising strategy for peptide and protein drugs by oral administration.

show abstract

Purification, biochemical properties and antithrombotic effect of a novel Streptomyces enzyme on carrageenan-induced mice tail thrombosis model

Cited by 44 publications

References 30 publications

Methods available to assess therapeutic potential of fibrinolytic enzymes of microbial origin: a review

Methods available to assess therapeutic potential of fibrinolytic enzymes of microbial origin: a review

Carrageenan-Induced Colonic Inflammation Is Reduced in Bcl10 Null Mice and Increased in IL-10-Deficient Mice

Preparation and evaluation of nattokinase-loaded self-double-emulsifying drug delivery system

Contact Info

Product

Resources

About